Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
52 hedge funds and large institutions have $22.7M invested in Cidara Therapeutics in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 7 closing their positions.
7,700% more call options, than puts
Call options by funds: $78K | Put options by funds: $1K
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
0% more funds holding
Funds holding: 52 → 52 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
0.12% less ownership
Funds ownership: 1.46% → 1.33% (-0.12%)
24% less capital invested
Capital invested by funds: $29.7M → $22.7M (-$6.99M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$134K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$83.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$76.7K |
| 4 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$53.4K |
| 5 |
Renaissance Technologies
New York
|
+$49.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.4M |
| 2 |
Morgan Stanley
New York
|
-$250K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$242K |
| 4 |
Two Sigma Investments
New York
|
-$164K |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$154K |
CDTX Hedge Fund Activity: Q3 2023 in Review
52 of the 6,309 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q3 2023, worth a combined $22.7M — down 24% from $29.7M a quarter earlier.
Fund positioning in CDTX was balanced in Q3 2023: 7 funds opened new positions, 7 closed out, 13 added to existing stakes and 12 trimmed.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $134K. The largest seller was Nantahala Capital Management, cutting an estimated $1.4M.
- 52 institutional investors held Cidara Therapeutics (CDTX) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $22.7M of Cidara Therapeutics stock for Q3 2023, down 24% quarter-over-quarter.
- 7 funds opened new Cidara Therapeutics positions in Q3 2023 and 7 closed out, a net change of 0 holders.
- The largest Cidara Therapeutics buyer in Q3 2023 was GSA Capital Partners, an estimated $134K added.
- The largest Cidara Therapeutics seller in Q3 2023 was Nantahala Capital Management, an estimated $1.4M sold.
Based on aggregated 13F filings for Q3 2023.